Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib + Letrozole in ER+ Endometrial Cancer
NCT02730429Phase 2Completed
- Sponsor
- Nordic Society of Gynaecological Oncology Clinical Trial Unit
- Start
- Feb 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in endometrial cancer (EC) comparing Letrozole + Placebo with Letrozole + Palbociclib (2 arms). Primary endpoint: Progression-Free Survival at 26 months. Started Feb 2017; status: completed.
02
Drugs
palbociclib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT02730429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02730429.